甲状腺功能低下症老年患者心血管死亡趋势:回顾性CDC奇迹分析 (1999-2020年)
Piyush Ratan1, Kritika2, Yashaswi Guntupalli3
1From the Department of Medicine, Patna Medical College, Patna, India.
Cardiology in review
|November 18, 2025
概括
患有甲状腺功能低下症的老年患者的心血管疾病死亡率正在上升,特别是在女性和非大都市地区. 这一趋势凸显了针对性干预措施的必要性,以减少该人口中的心血管死亡率.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 公共卫生 公共卫生
背景情况:
- 甲状腺功能低下症越来越多地与心血管疾病 (CVD) 风险有关.
- 了解甲状腺功能低下患者心血管疾病死亡率趋势对于公共卫生战略至关重要.
研究的目的:
- 评估1999年至2020年美国老年患有甲状腺功能低下症的患者心血管死亡趋势.
- 确定甲状腺功能低下个体中心血管疾病死亡率的人口和地理差异.
主要方法:
- 利用美国死亡率数据 (1999-2020) 的Joinpoint回归分析.
- 每10万人口计算的原始和年龄调整的死亡率 (AAMR).
- 研究了跨年龄组,性别,种族和城市化水平的趋势.
主要成果:
- 在甲状腺功能低下患者中,共发生了351,857例心血管疾病死亡,平均年增长率为0.7%.
- 高血压疾病,缺血性心脏病,心力衰竭和中风是主要原因.
- 女性,非西班牙裔白人和非大都市地区的个人显示出更高的AAMR.
结论:
- 甲状腺功能低下症患者的心血管死亡率有所增加,特别是在过去十年.
- 存在显著的差异,女性,老年人 (85岁以上) 和非大都市地区的死亡率更高.
- 需要进一步的研究来解决推动这些趋势和差异的因素.
相关概念视频
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Drug Dosing: Geriatric Patients
214
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
214
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
186
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
186
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
223
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
223
Hypertension II: Pathophysiology
763
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
763
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
217
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
217

